Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up

Tumor Biology ◽  
2015 ◽  
Vol 36 (10) ◽  
pp. 8193-8200 ◽  
Author(s):  
Marko Buta ◽  
Radan Džodić ◽  
Igor Đurišić ◽  
Ivan Marković ◽  
Tijana Vujasinović ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Histological Grade ◽  
Postmenopausal Breast Cancer ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Grade Ii ◽  
Pai 1

Prognostic importance of PAI-1 in node negative breast cancer patients—Results after 10 years of follow up

2011 ◽  
Vol 207 (5) ◽  
pp. 290-294 ◽  
Author(s):  
Domagoj Eljuga ◽  
Jasminka Jakic Razumovic ◽  
Kresimir Bulic ◽  
Marko Petrovecki ◽  
Natasa Draca ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Prognostic Importance ◽  
Pai 1

scholarly journals Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study

The Breast ◽  
2016 ◽  
Vol 29 ◽  
pp. 102-108 ◽  
Author(s):  
An De Groef ◽  
Marijke Van Kampen ◽  
Elena Tieto ◽  
Petra Schönweger ◽  
Marie-Rose Christiaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Upper Limb ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Follow Up Study ◽  
Node Negative Breast Cancer ◽  
Arm Lymphoedema ◽  
One Year

scholarly journals Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 ◽  
Vol 15 (1) ◽  
pp. 73-78 ◽  
Author(s):  
A. Prechtl ◽  
N. Harbeck ◽  
C. Thomssen ◽  
C. Meisner ◽  
M. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Systemic Therapy ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

In axillary node-negative primary breast cancer, 70% of the patients will be cured by locoregional treatment alone. Therefore, adjuvant systemic therapy is only needed for those 30% of node-negative patients who will relapse after primary therapy and eventually die of metastases. Traditional histomorphological and clinical factors do not provide sufficient information to allow accurate risk group assessment in order to identify node-negative patients who might benefit from adjuvant systemic therapy. In the last decade various groups have reported a strong and statistically independent prognostic impact of the serine protease uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor type 1) in node-negative breast cancer patients. Based on these data, a prospective multicenter therapy trial in node-negative breast cancer patients was started in Germany in June 1993, supported by the German Research Association (DFG). Axillary node-negative breast cancer patients with high levels of either or both proteolytic factors in the tumor tissue were randomized to adjuvant CMF chemotherapy versus observation only. Recruitment was continued until the end of 1998, by which time 684 patients had been enrolled. Since then, patients have been followed up in order to assess the value of uPA and PAI-1 determination as an adequate selection criterion for adjuvant chemotherapy in node-negative breast cancer patients. This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies.

Randomized cooperative study of perioperative chemotherapy in breast cancer.

1995 ◽  
Vol 13 (11) ◽  
pp. 2712-2721 ◽  
Author(s):  
M R Sertoli ◽  
P Bruzzi ◽  
P Pronzato ◽  
P Queirolo ◽  
D Amoroso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Preliminary Evidence ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Node Negative ◽  
Significant Survival ◽  
Significant Difference ◽  
Estrogen Receptor Negative

PURPOSE The aim of this multicentric randomized trial was to determine whether reducing the interval between surgery and chemotherapy improves the outcome of breast cancer patients. PATIENTS AND METHODS Between June 1985 and July 1992, 600 breast cancer patients, clinical stages T1-3A,N0-2,M0 were randomly assigned to a perioperative cycle (PC) of cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF). Node-negative (N-) patients did not receive any further treatment. Node positive (N+) patients received 11 cycles if previously given PC, or 12 cycles of CEF alternated with cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2 (CMF). In addition, N+ patients received concomitant or sequential 5-year tamoxifen therapy. RESULTS At a median follow-up duration of 5.7 years, no significant difference in survival (88% v 84%, P = .3) between the two treatment arms was seen. However, a difference of borderline significance in relapse-free survival (RFS; 76% v 70%, P = .053) was evident. A significant survival advantage for the PC arm was detected only in the estrogen receptor-negative (ER-) patients (P = .003). RFS was significantly improved in N- patients, postmenopausal patients, and ER- patients. Multivariate analyses show that pathologic tumor size, nodal status, receptor status, and treatment (only in ER- patients) are significantly correlated with survival and RFS. PC toxicity did not influence wound healing. CONCLUSION This study provides preliminary evidence that PC positively affects relapse rate and survival in some subgroups, namely, ER- patients.

Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation.

1997 ◽  
Vol 15 (6) ◽  
pp. 2329-2337 ◽  
Author(s):  
R Heimann ◽  
D Ferguson ◽  
C Powers ◽  
D Suri ◽  
R R Weichselbaum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Racial Differences ◽  
Multivariable Analysis ◽  
Disease Free Survival ◽  
Similar Proportion ◽  
Significant Variable ◽  
Breast Cancer Patients ◽  
Node Negative

PURPOSE To compare the outcome of African American (AA) and Caucasian (C) breast cancer patients who had equivalent disease extent and were similarly treated. PATIENTS AND METHODS We compared prognostic characteristics, treatment, and outcome of 1,037 C and 481 AA breast cancer patients treated with mastectomy between 1946 and 1987. The median follow-up duration was 15.6 years. RESULTS During the study period, there was a successive increase in the percent of patients who presented with early breast cancer. Between 1980 and 1987, 35.1% AA versus 47.6% C patients had < or = 2-cm tumors and 50.0% AA versus 61.9% C patients were node-negative, while between 1946 and 1959, 27.7% AA and 31.3% C had < or = 2-cm tumors and 41.5% AA versus 40.4% C patients were node-negative. The treatments were similar during the study period. The 20-year disease-free survival (DFS) rate of AA compared with C patients with node-negative < or = 2-cm, 2.1- to 4-cm, and greater than 4-cm tumors and of patients with one to three and > or = four positive nodes was not significantly different. Equal-size tumors had similar proportion of positive axillary nodes in AA compared with C patients. The DFS for AA patients compared with C patients was similar in the periods 1946 to 1959, 1960 to 1969, and 1970 to 1979, but was lower between 1980 and 1987 (P = .02). In multivariable analysis, race was not a significant variable. CONCLUSION In this large group of uniformly treated breast cancer patients, race was not an independent factor that influenced outcome. The racial differences seen between 1980 and 1987 are likely because of a larger percent of greater than 2-cm and node-positive tumors in AA patients. Education and access to early diagnosis should reduce or eliminate the racial differences seen.

scholarly journals Decreased FOXF2 mRNA Expression Indicates Early-Onset Metastasis and Poor Prognosis for Breast Cancer Patients with Histological Grade II Tumor

PLoS ONE ◽  
2013 ◽  
Vol 8 (4) ◽  
pp. e61591 ◽  
Author(s):  
Peng-Zhou Kong ◽  
Fan Yang ◽  
Lin Li ◽  
Xiao-Qing Li ◽  
Yu-Mei Feng
Keyword(s):  
Breast Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Early Onset ◽  
Poor Prognosis ◽  
Histological Grade ◽  
Breast Cancer Patients ◽  
Grade Ii

Incidence of Axillary Recurrence in 344 Sentinel Node Negative Breast Cancer Patients after Intermediate Follow-Up

2008 ◽  
Vol 108 (2) ◽  
pp. 203-207 ◽  
Author(s):  
E.M. Heuts ◽  
F.W.C. van der Ent ◽  
K.W.E. Hulsewé ◽  
P.A.M. Heeren ◽  
A.G.M. Hoofwijk
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Axillary Recurrence ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

Clinical relevance of HER-2 expression in node-negative breast cancer patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 598-598
Author(s):  
J. M. Sun ◽  
W. Han ◽  
D. W. Kim ◽  
T. Y. Kim ◽  
I. A. E. Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document